It is very uncertain whether colchicine changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
It is very uncertain whether insulin plus glucagon changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
It is very uncertain whether transarterial embolisation and transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
It is very uncertain whether transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
It is very uncertain whether transarterial embolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
It is very uncertain whether percutaneous ethanol injection changes mortality at last compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
The review found no eligible studies for this question.
Lidocaine showed no clear difference in cardiac mortality compared with placebo or no intervention (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether multidisciplinary disease management programmes changes HF mortality compared with usual care (very low certainty).